All In Biotech

Drug Trial Radar · NCT03932643

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

A Phase 1 Trial of ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After an Allogeneic Hematopoietic Stem Cell Transplant

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jul 30, 2019

Primary completion

Mar 27, 2025

Study completion Mar 27, 2025

Sponsor

Lead sponsor
University of NebraskaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center Phase 1 trial of 20 patients with AML/MDS. Eligible patients will be enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem cell transplant. Patients will receive weekly oral ONC 201 for a total of 52 weeks.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes

Interventions

  • ONC-201Drug

    ONC-201 Capsules, 125 mg Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dose limiting toxicities during the first cycleTime frame: after one month of treatment
  2. Grade ≥3 toxicitiesTime frame: during the first 3 cycles of treatment (each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Nebraska Medical Center

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.